Advisor Group’s Intellia Therapeutics NTLA Stock Holding History

Advisor Group’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$48K	Hold	3,246	–	–	﹤0.01%	3441
2019 Q3	$44K	Hold	3,246	–	–	﹤0.01%	3482
2019 Q2	$54K	Hold	3,246	–	–	﹤0.01%	3303
2019 Q1	$56K	Hold	3,246	–	–	﹤0.01%	3297
2018 Q4	$45K	Buy	3,246 +283	+10%	+$5.26K	﹤0.01%	3252
2018 Q3	$84K	Sell	2,963 -439	-13%	-$12.8K	﹤0.01%	2885
2018 Q2	$93K	Buy	3,402 +800	+31%	+$19.4K	﹤0.01%	2580
2018 Q1	$55K	Hold	2,602	–	–	﹤0.01%	2987
2017 Q4	$50K	Buy	2,602 +1,564	+151%	+$36.1K	﹤0.01%	3084
2017 Q3	$26K	Buy	1,038 +998	+2,495%	+$18.8K	﹤0.01%	3409
2017 Q2	$1K	Hold	40	–	–	﹤0.01%	4645
2017 Q1	$1K	Hold	40	–	–	﹤0.01%	4552
2016 Q4	$1K	Hold	40	–	–	﹤0.01%	4377
2016 Q3	$1K	Hold	40	–	–	﹤0.01%	4327
2016 Q2	$0	Buy	+40	New	+$1.06K	﹤0.01%	4458

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Advisor Group's NTLA Position: Q4 2019 in Review

Advisor Group held its Intellia Therapeutics (NTLA) position steady in Q4 2019 at 3,246 shares worth $48K. The position accounts for ﹤0.01% of the portfolio, ranked #3441.

Advisor Group first reported a position in NTLA in Q2 2016 and has held it in 15 quarters since. The position peaked at $93K in Q2 2018. 143 funds tracked by Wall St. Rank hold NTLA as of Q4 2019.

Advisor Group held 3,246 shares of Intellia Therapeutics worth $48K as of Q4 2019.
Advisor Group left its Intellia Therapeutics share count unchanged in Q4 2019.
Intellia Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #3441 holding.
Advisor Group first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 15 quarters since.
Advisor Group's Intellia Therapeutics position peaked at $93K in Q2 2018.
143 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.